Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Calculated resectability vs. evaluated resectability

From: Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma – results of the Conko-007 multicenter trial

  Surgeon A Surgeon B Surgeon C Surgeon D Surgeon E
Agreement between Surgeon and ISGP 76.1% 83.4% 74.1% 72.9% 79.8%
Disagreement 23.9% 16.6% 25.9% 27.1% 20.2%
Surgeon ISGP  
Resectable Locally advanced 1.0% 1.0% 1.3% 2.6% 4.6%
Resectable Borderline resectable 7.3% 3.5% 13.9% 18.8% 9.6%
Locally advanced Resectable 0.5% 2.5% 0% 0% 0%
Locally advanced Borderline resectable 0% 0% 1.9% 0.5% 0%
Undetermined Resectable 6.8% 2.5% 2.5% 1.6% 2.0%
Undetermined Locally advanced 8.3% 7.1% 6.3% 3.6% 4.0%
  1. Resectability was calculated from the single items assessed by the 5 surgeons according to ISGPS recommendations. The resectability calculated from the assessment of tumor abutment to peripancreatic vascular structures was compared to the judgement of resectability given by the evaluating surgeon